Biorasi Acquires European CRO, Advanced Biosciences Research

Published on: 

Company News Release

Leading Global CRO Expands into Western Europe, Establishes its European Headquarters in Frankfurt, Germany

Biorasi LLC, award-winning global CRO, announced today that it has completed the acquisition of Advanced Biosciences Research (ABR), a leading European CRO with operations in United Kingdom, Germany, Switzerland, and Sweden. ABR is a highly integrated group that has provided Phase II to IV clinical research project management, monitoring, and regulatory outsourcing for its sponsors in the region.

"This move is strategically crucial to addressing the ever-increasing demand for delivering Clinical Research Optimized™ globally," explained Dr. Boris Reznik, Chairman of Biorasi. "Our ProAct+™ platform is the foundation of unparalleled global integration of our project operations. It guides, adapts and improves every clinical trial planning and execution process. Expanding our Western European Operations dramatically increases its optimization capability."

"We have been working with Biorasi for over a year and have been extremely impressed with the superiority of Biorasi's innovative clinical research project delivery model. Its ProAct+™ platform does not have equals in our industry." explained Dr. Tigran Arzumanov, ABR Principle. "We are excited to be a part of Biorasi's team."

Biorasi has been running world-wide clinical trials for over a decade.It has maintained a formidable presence in North and South America, Eastern Europe and Asia. The addition of ABR's regional base to Biorasi unmatched strength in Russia and Ukraine, and a decade-long established presence in Czech Republic, Poland, Serbia, Latvia, and United Kingdom, creates a very strong footprint throughout Europe.